News Summary

• The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions.
• This change improves the transparency of Bioretec's performance in its core business and ensures alignment with industry practices.
• The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery.
• The RemeOs™ product line is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes.